Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526121 | 0.90 | AAK1 (0.43) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL31752616 | 0.88 | AAK1 (0.39) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL1484818 | 0.73 | FFAR1 (0.60) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL33526681 | 0.71 | AAK1 (0.37) | AAK1 | |
| SCHEMBL16739782 | 0.71 | LPL (0.33) | FFAR1 | |
| SCHEMBL31752062 | 0.70 | TP53 (0.31) | — | |
| SCHEMBL33526119 | 0.67 | AAK1 (0.37) | AAK1 | |
| SCHEMBL33526103 | 0.67 | AR (0.40) | AAK1 | |
| SCHEMBL33527256 | 0.67 | LMNA (0.48) | — | |
| SCHEMBL31752066 | 0.66 | TP53 (0.37) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | AAK1 2749/4885PRMT5 2639/4885WDR77 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.